Trial reportDrug design, development and therapy2026
Effect of Lidocaine Spray on the Sedative Dose of Remimazolam During Gastroscopy in Adults: A Prospective, Randomized Dose-Response Trial Using an Up-Down Sequential Allocation Method.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the effect of oropharyngeal topical lidocaine spray on the sedative dose of remimazolam required for gastroscopy in adults. Patients and Methods: Patients undergoing painless gastroscopy at our hospital were selected and randomly divided into a lidocaine spray group (Group L) and a control group (Group C) using a random number table method, with 25 patients enrolled in Group L and 24 patients enrolled in Group C. Patients in Group L received oropharyngeal spray containing lidocaine aerosol (approximately 16 mg of lidocaine per spray), with two sprays administered. Patients in Group C received oropharyngeal spray containing normal saline aerosol. At the start of sedation, alfentanil was intravenously injected at a dose of 3 μg/kg, followed by remimazolam administration using a sequential method. The initial intravenous dose of remimazolam was 0.2 mg/kg, with a dose adjustment gradient of 0.02 mg/kg. The median effective dose (ED50) of remimazolam for successful first-dose sedation during gastroscopy was calculated using probit regression analysis. Results: The ED50 (95% confidence interval) of remimazolam in Group L was 0.149 (0.125-0.167) mg/kg, while that in Group C was 0.191 (0.147-0.217) mg/kg. The relative median potency between the two groups was 0.783 (95% CI: 0.381-0.959). In addition, no statistically significant differences were observed in hemodynamic changes or related adverse events between the two groups (P > 0.05). Conclusion: Lidocaine spray can be used in combination with remimazolam for gastroscopic examination to reduce the sedative dose of remimazolam during gastroscopy in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.